Sign up
Pharma Capital

Avacta firmly focused on first-in-human Affimer therapeutic trial

Alastair Smith, chief executive of Avacta Group PLC (LON:AVCT) tells Proactive London's Andrew Scott all is on track to begin a Phase I clinical trial of its first Affimer therapeutic candidate next year.

The company is soon to start manufacturing its PD-L1 inhibitor – called AVA004-251 – which will then allow it to file a clinical trial application, asking regulators to let it test the drug on humans.

 

View full AVCT profile View Profile
CN Research

Avacta - interim results confirm progress

View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.